AnaptysBio (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
Top Page
AnaptysBio
(NASDAQ:ANAB)
Select Model
Select Model
Rating:60Neutral
Price Target:
$66.00
▼(-2.24% Downside)
Action:Reiterated
Date:05/14/26
The score is driven by strong technical strength (clear uptrend with supportive momentum) but capped by mixed fundamentals—improving operations and cash generation offset by volatile TTM results and a weakened balance sheet. Valuation also weighs on the score due to continued net losses (negative P/E), while recent corporate actions are a moderate positive tailwind.
Positive Factors
Royalty-focused business model
The corporate split leaves AnaptysBio focused on managing royalty streams (Jemperli, imsidolimab) rather than capital‑intensive R&D. This creates a more predictable, lower‑capex cash profile and aligns the firm toward steady cash receipts and portfolio monetization over time.
Negative Factors
Weakened balance sheet
Trailing‑period deterioration in equity and rising leverage materially reduces financial flexibility. Higher debt ratios increase interest and covenant risk, limiting ability to absorb timing gaps in royalty receipts or to opportunistically fund buybacks or distributions without refinancing.
Read all positive and negative factors
Positive Factors
Negative Factors
Royalty-focused business model
The corporate split leaves AnaptysBio focused on managing royalty streams (Jemperli, imsidolimab) rather than capital‑intensive R&D. This creates a more predictable, lower‑capex cash profile and aligns the firm toward steady cash receipts and portfolio monetization over time.
Read all positive factors
AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.74B
Dividend YieldN/A
Average Volume (3M)665.44K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth107.73%
EPS Growth82.33%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding29,100,903
10 Day Avg. Volume532,003
30 Day Avg. Volume665,444
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue11.20
Enterprise Value/Gross Profit9.62
Enterprise Value/Ebitda48.82
Forecast
1Y Price Target
$81.36Price Target Upside20.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.04
Revenue Forecast (FY)$125.27M
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 recepto...
How the Company Makes Money
AnaptysBio makes money primarily through collaboration and licensing arrangements rather than product sales (its programs are largely in clinical development). Under these types of deals, revenue is typically generated from (1) upfront payments re...
AnaptysBio Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
45
Neutral
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 232.39M | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 270.54M | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 53.33M | 50.32M | -92.74M | -156.42M | -105.26M | -55.71M |
| Net Income | -26.79M | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | ||||||
| Total Assets | 329.68M | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 286.45M | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 277.36M | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 316.94M | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 12.75M | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | ||||||
| Free Cash Flow | 4.41M | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 4.48M | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 248.17M | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -102.81M | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Neutral
67.51
Price Trends
52.44
Positive
43.32
Positive
32.35
Positive
Market Momentum
2.02
Positive
50.71
Neutral
23.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Neutral. The current price of 67.51 is above the 20-day moving average (MA) of 64.52, above the 50-day MA of 52.44, and above the 200-day MA of 32.35, indicating a neutral trend. The MACD of 2.02 indicates Positive momentum. The RSI at 50.71 is Neutral, neither overbought nor oversold. The STOCH value of 23.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AnaptysBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $1.74B | -5.01 | 442.91% | ― | 107.73% | 82.33% | |
56 Neutral | $855.71M | -3.80 | 474.91% | ― | 131.13% | 35.61% | |
54 Neutral | $221.47M | -4.33 | -17.04% | ― | -84.55% | -1998.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.19B | -7.22 | -45.95% | ― | ― | -3.83% | |
42 Neutral | $372.78M | -13.46 | -39.75% | ― | -100.00% | -2.72% |
* Healthcare Sector Average
ANAB
AnaptysBio
59.71
46.09
338.27%
MGTX
Meiragtx Holdings
9.24
4.14
81.18%
KROS
Keros Therapeutics
11.19
-3.16
-22.02%
CMPX
Compass Therapeutics
2.07
-0.04
-1.90%
OLMA
Olema Pharmaceuticals
13.68
8.53
165.63%
AnaptysBio Corporate Events
Executive/Board Changes
AnaptysBio Appoints New CFO and Board Director
Positive
May 11, 2026
On May 11, 2026, AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer, formalizing his role through a consulting agreement that designates him as an independent contractor with performance-based compensation and a $1.75 mill...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
Positive
Apr 20, 2026
On April 20, 2026, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, separating its biotechnology RD operations from a royalty-focused business that will retain and manage Jemperli and imsidolimab royalty streams and related colla...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
Positive
Mar 27, 2026
AnaptysBio, Inc. is a biotechnology company that is spinning out First Tracks Biotherapeutics as a separate, clinical-stage biotech focused on next-generation antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.